9 results
8-K
EX-99.1
TLPH
Talphera Inc.
6 Nov 19
AcelRx Pharmaceuticals Reports Third Quarter 2019 Financial Results
4:26pm
of Acute Pain"
Pooled dosing and efficacy data from use of the sufentanil sublingual tablet (SST) 30 mcg among multiple demographic subgroups (age, sex
8-K
EX-99.1
TLPH
Talphera Inc.
17 May 21
AcelRx Pharmaceuticals Reports First Quarter 2021 Financial Results
4:10pm
profile for all demographic subgroups following the dosing of DSUVIA. See Cautionary Statements section below.
In March 2021, AcelRx announced
8-K
EX-1.1
e42lwgxqq nwmf
13 Jul 18
Other Events
4:03pm
8-K
EX-1.1
yj3ph kn37gc8c
21 Jan 21
Entry into a Material Definitive Agreement
5:29pm
8-K
EX-1.1
ap32guy56rna kcd
13 Nov 18
Other Events
5:18pm
- Prev
- 1
- Next